I attended the Synairgen AGM last Friday (June 22nd 2018), which was held at the offices of Fladgate LLP, 16 Great Queen Street, London. For investors who is unfamiliar with the company, Synairgen is an AIM listed UK based biotech company focused primarily on developing new treatments for Asthma, COPD and other respiratory diseases. The […]
This content is restricted to ShareSoc full members only. If you are a full member, please login here to view the full article. If not, please subscribe here to gain access.